This is a StreetInsider.com Premium Only Page

Soligenix, Inc. (SNGX) – Newsfile

Nov 11, 2022 09:30 AM Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference

Oct 13, 2022 08:30 AM Soligenix Enters Q4 With Multiple Catalysts in Play

Sep 12, 2022 08:30 AM FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL

Jul 26, 2022 09:27 AM Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients

Jun 7, 2022 08:30 AM Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis

Mar 1, 2022 03:04 PM Soligenix, Inc. to Present at the Q1 Virtual Investor Summit

Jan 12, 2022 12:00 PM Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

Nov 30, 2021 08:30 AM Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers

Oct 13, 2021 08:30 AM Highlights and Insights into Soligenix

Sep 14, 2021 08:30 AM Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics

Jul 29, 2021 08:30 AM Who Is Preparing Us for the Next Potential Pandemic?

Jul 22, 2021 08:30 AM HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma

Jul 6, 2021 08:30 AM Offering New Hope for a Rare Form of non-Hodgkin's Lymphoma: A Discussion with Dr. Ellen Kim on HyBryte(TM) from Soligenix

Jun 3, 2021 08:30 AM Shining a Light on Soligenix's HyBryte(TM) Growth Opportunity